Pharmaceuticals And Biotech Are A Hot Space For Activists Right Now

Since it has been a relatively quiet week – for proxy season, at least – I want to provide a little bit more insight into one of our two feature articles from the April issue.

It’s something of an irony that just as Bill Ackman decides to get out of Valeant Pharmaceuticals International, the rest of the activist community appears to be refocusing on the sector. Perhaps it’s a function of real estate faltering a little or oil prices failing to stabilize (though the outlook is better than it was a while ago). Perhaps it has to do with Trump winning the election, although his policy on drug pricing may turn out to be as harsh as Clinton’s.